Tag: antibody

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, in 2019. It is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic. In addition to SARS-CoV-2, six other coronaviruses are known, among which four are seasonal human coronaviruses and cause mild self-limiting upper respiratory tract infections. Study: Humoral response to

A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England

Sex-based differences in COVID-19 disease transmission, severity, and mortality have been reported since the early stages of the pandemic in infants, with the underlying mechanism accounting for these differences not yet fully understood. In a paper recently published in the journal Science Translational Medicine by Bordt et al. (October 19th, 2021), maternal SARS-CoV-2 infections are

The coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection with SARS-CoV-2 produces B cell responses that persist for at least one year. Thus, immunological memory is essential to prevent re-infection, and B cells play a vital role in this aspect of the defense mechanism provided by the immune system.

The coronavirus disease 2019 (COVID-19) pandemic spread rapidly around the world, leading to lockdowns, social distancing measures, and millions of deaths. However, with the help of mass vaccination campaigns and monoclonal antibody treatments, the transmission of the disease is beginning to slow down. Vaccines rely on the immune systems ability to produce specific antibodies –

A novel combination treatment may increase the ability of monoclonal antibodies to control viral infection in patients diagnosed with HIV, according to a Northwestern Medicine study published in Science Translational Medicine. This really demonstrates that that we should combine broadly neutralizing antibodies with other immunostimulatory agents, especially those that may impact immune response. If we

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19. Image Credit: ExeVir Bio The randomized, double-blinded, single-center, placebo-controlled Phase I clinical study will

To date, the ongoing novel coronavirus disease 2019 (COVID-19) – caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – has led to over 192.17 million confirmed cases and over 4.13 million deaths. However, it is only the seventh pathogenic human coronavirus to be identified. A new study, recently released as a preprint on

Researchers at the University of Turku, Finland, showed that the antibody treatment reactivates the immune defense in patients with advanced-stage cancer. The treatment alters the function of the body's phagocytes and facilitates extensive activation of the immune system. The immune defense is the body's own defense system equipped to combat cancer. However, cancer learns to

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals. Study:

FDA authorizes third Covid antibody treatment that cuts risk of hospitalization or death by 85% Sotrovimab is the third monoclonal antibody drug to receive approval for use fighting Covid-19, fifth drug overall Believed to be able to reduce Covid hospitalizations and deaths by 85 percent   The drug will be the first to have a point

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19). Study: Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

FILE PHOTO: A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar(Reuters) -Eli Lilly and Co said on Monday it had a revised agreement with the U.S. government for its COVID-19 antibody drug, bamlanivimab,

Most people with cancer who are infected by the novel coronavirus produce antibodies at a rate comparable to the rest of the population–but their ability to do so depends on their type of cancer and the treatments they've received, according to a new study by researchers at Montefiore Health System and Albert Einstein College of

Six months after it was controversially hailed by Trump administration officials as a "breakthrough" therapy to fight the worst effects of Covid-19, convalescent plasma appears to be on the ropes. The treatment that infuses blood plasma from recovered Covid patients into people newly infected in hopes of boosting their immune response has not lived up

New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or

The coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc across the globe. Scientists are racing to develop effective therapeutic regimens to combat the infection. One of therapy currently used to stimulate a robust immune response against the virus is monoclonal antibodies, a treatment used for

The coronavirus disease 2019 (COVID-19) pandemic – caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – is still causing hundreds of thousands of new cases globally. Therapeutic antibodies have been used to attempt to counter and contain the virus. Convalescent plasma (CP) obtained from recovered COVID-19 patients is also in use in many

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School of Medicine report that individual

Researchers at the California Institute of Technology in Pasadena have developed a software tool called "Variant Database" that has detected an emerging lineage of severe acute respiratory coronavirus 2 (SARS-CoV-2) isolates in New York. The novel SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to sweep the globe